Principles and Scientific Basis of Traditional Chinese Medicine in Cancer Treatment

Bing Hu*, Qin Du, Ke-Ping Shen and Ling Xu

Department of Oncology and Institute of Traditional Chinese Medicine in Oncology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, PR China

Abstract

Traditional Chinese Medicine (TCM) have been used to reduce toxic effects and enhance therapeutic effects of modern cancer therapy, palliate clinical syndrome or improve quality of life, enhance immune function, prevent recurrence and metastasis, and anti-cancer therapy for patients failed in or refuse to conventional treatment. From TCM perspective, the pathogenesis of cancer is related to weakened body resistance, blood stasis, phlegm stagnation and toxicity accumulation, and cancer are recognized as syndrome of blood-stasis, phlegm and toxicity in TCM. Syndrome Differential Treatment is the basic principle for cancer treatment. Anti-cancer effects of Chinese herb are associated with apoptosis, cell senescence, autophagy and other mechanisms. Chinese herbal formula is the major application form of Chinese herb. Most TCM physicians prescribe or combine multiple herbs for a formula or prescription based on TCM principles, pharmacological progression and personal experience. We emphasize application of anti-cancer herb must guided by TCM principles. There is a great need to explore the combination rule of anti-cancer herbs, and establish effective herbal formulas for various situations in cancer treatment.

Keywords: Cancer; Traditional Chinese medicine; pathogenesis; Chinese herbal formula; effective mechanisms

Introduction

Cancer has become the global healthy problem. According to global statistics, 12.7 million cancer cases and 7.6 million cancer deaths occurred in 2008 worldwide [1]. For most cancer patients, surgery, radiotherapy and chemotherapy are the main conventional therapies. In recent years, accumulated investigations are focus on cancer biological therapies such as immunotherapy, gene therapy, and targeted therapy. These therapies are expensive and unbearable for some patients due to serious side effects. Cancer remains the leading cause of death in economically developed countries and the second leading cause of death in developing countries [2]. There is a great need to develop new approach for cancer prevention and treatment. Ethnomedicine, including Traditional Chinese Medicine (TCM), may provide new contribution to cancer treatment.

Understanding of Traditional Chinese Medicine in Cancer

In china, TCM have long been used for treatment of various diseases including cancer. The word cancer was first described in inscriptions on bones or tortoise shells in the Shang dynasty (6th-11th century BC). Cancer related clinical manifestation and causes have been well described in Chinese medical literature since 400 BC [3]. As a malignant lesion, cancer was first appeared in the book of Wei-Ji-Bao-Shu (AD 1170). Cancer was well described by Yang SY, a famous doctor in the Song dynasty, in the book of Ren-Zhai-Zhi-Fu-Yi-Fang-Lun (AD 1264), which described them as masses that were rock-like and had uneven surfaces. As a new discipline, TCM oncology was rapidly developed in recent 60 years.

Holistic view is the basic characteristic of TCM. From TCM perspective, cancer is a systemic disease and the uncontrolled growth of tumor mass is only part of the whole sophisticated manifestations. Cancer patients also have certain body dysfunctions and even meridian disorders, and show different TCM syndromes. TCM believes a weakened body anti-disease capabilities (vital Qi) is the basis of carcinogenesis, which makes individuals susceptible to different carcinogenic factors, such as environment and diet factors. In addition to extrinsic carcinogenic factors, congenital deficiencies, emotional stress and lifestyle and also play a role in carcinogenesis. Body and carcinogenic factor interaction result in internal disharmony, and leading to accumulation of pathological products, such as blood-stasis, phlegm and toxicity. Qi-stagnation and Blood-stasis, phlegm retention and toxicity accumulation are the general pathological characteristics of all cancers [3-7]. The cancer progression due to the body anti-disease capabilities (vital Qi) can’t eliminate pathological products timely. Cancer can be healing with promoting body resistance and eliminating pathological products.

Present Situation of TCM in Cancer Treatment

Present in china, almost all cancer patients in China. Over a long-term practice, TCM has accumulated various methods for cancer treatment, such as Chinese herb, acupuncture and moxibustion, and Qi Gong. TCM have been integrated to modern comprehensive therapy during the past 60 years due to the changes of cancer therapeutic model. At present, TCM have been widely used to reduce toxic side effects and enhance effects of conventional therapies.
modern therapeutics, palliate clinical syndrome or improve quality of life, enhance immune function, prevent recurrence and metastasis, and the last hope for patients failed in or refuse to conventional treatment. However, anti-cancer is the most common reason for patients to seek TCM treatment.

**Syndrome Differential Treatment in Cancer**

In Traditional Chinese Medicine, “treatment according to syndrome differentiation” is the basic principle for all clinical applications. Based on patient’s condition and their different phases of cancer, TCM use its unique examination techniques and theories, then make diagnosis and select appropriate treatment method(s) as well as predict prognosis for each cancer patient. According to different TCM syndrome of cancer patients, TCM physicians may employ different Chinese herbs, acupuncture and moxibustion, or Qi Gong for cancer treatment. Chinese herbs are the major approach for anti-cancer or symptomatic treatment. Under the guidance of Syndrome Differential Treatment, patients with different cancers but have the same syndrome can be treated by the same TCM treatment law. However, one TCM treatment law may include different herbs with similar efficacy. Such as Panax Ginseng, Astragalus Membranaceus and Atractyloides Rhizome can be assigned to Qi-tonifying herbs, and Barbed Skullcap, Oldenlandia Diffusa and Rhizoma Pardis can be assigned to heat-clearing and detoxifying anti-cancer herbs. On the other hand, different treatment law will be adopted in patients with same cancer but different syndrome. These are just the theories of “same treatment for different disease” and “same disease treatment with different methods” in TCM.

For example, as a splenic Qi-tonifying herb, Atractyloides Rhizome can be used for all cancer patients with splenic qi-deficiency. As a Qi and blood-tonifying herb formula, Dang-Gui-Bu-Xue-Tang, an ancient herb formula, can be prescribed to all cancer patients with Qi and blood-deficiency to improve bone marrow hematopoietic function. In primary hepatocarcinoma patients, based on different syndrome patterns, physicians may employ invigorating spleen and regulating Qi, clearing heat-dampness, dissipating stasis, softening hardness, or tonifying liver and kidney to cure cancer [8-11]. Syndrome differentiation treatment also acts an important role in treating adverse effects caused by radio- or chemotherapy [12]. Syndrome Differential Treatment is the essential principle of TCM in cancer treatment.

**Possible Relationship between TCM Syndrome and Modern Medicine**

It has been reported different stage of cancer, pathological type and even treatment may influence TCM syndrome distribution. Such as in Guangzhou area, spleen deficiency and Qi stagnation syndrome, Qi stagnation and blood stasis syndrome, spleen deficiency and damp-heat syndrome, and deficiency in liver and spleen syndrome are frequently observed in patients with stage II liver cancer. Liver and kidney Yin deficiency is the most common syndrome in patients with stage III liver cancer [13]. In gastric carcinoma, different TCM syndromes were related with gender, pathology, cell differentiation, infiltration depth, lymphaden metastasis, distant metastasis, and TNM stage. The common syndromes in female patients with gastric carcinoma were disharmony between liver and stomach, Yin impairment due to stomach heat, and insufficiency of both Qi and blood; while in males, interior retention of stagnant toxin, interior retention of phlegm and dampness, and deficiency-cold in spleen and stomach were common [15]. In lung cancer patients, deficiency of Qi, blood stasis, damp-phlegm and deficiency of Yin are main syndromes of TCM in adenocarcinoma and squamous carcinoma [14].

In addition, some genes may relate to differential syndrome. C-erb-B2, an important prognostic factor in breast cancer, has been reported highly expressed in breast cancer patients with blood stasis syndrome than the other syndromes [16]. In gastric carcinoma, the expression of E-cad was significantly higher in stomach heat due to Yin deficiency and exhaustion of both Qi and blood than in other syndromes. The level of MMP2 expression was markedly lower in incoordination between liver and stomach, stomach heat due to Yin deficiency, and insufficiency of spleen and stomach than that in retention of blood stasis toxin in the interior [17]. In lung cancer, genotypes of CYP1A1 MspI were reported associated to different TCM syndrome. The frequencies of CC genotype in essence and Qi deficiency syndrome were higher than that in other syndromes. CT was the main genotype in internal accumulation of phlegm-heat syndrome, while in internal heat due to Yin-deficiency syndrome CC was the main genotype [18].

Despite of endeavors were undertaken to explore the possible relationship between TCM syndrome and modern medicine. Current accumulated evidences are very preliminary; there is a long way to elucidate the factors that influence TCM syndrome formation and evolution, understand the possible scientific basis of TCM syndrome, translate opaque TCM theory and terminology into straightforward modern biomedical language, better guide TCM clinical practice of oncology, and ultimately improve TCM clinical efficacy in cancer treatment.

**Clinical Efficacy of TCM in Cancer Treatment**

During conventional chemotherapy, radiotherapy or targeted therapy, toxic side effects such as emaciation, fatigue, hair loss, rash, nausea, vomiting, diarrhea and leucopenia still bedevil patients. To relieve these symptoms is one of the most common reasons for cancer patients to seek TCM treatment in China. Clinical data shown TCM have a clear advantage in dealing with these symptoms. A double-blind placebo-controlled randomized clinical study confirmed Chinese herbal medicine does have a significant impact on control of chemotherapy-induced oral mucositis in breast cancer patients [20]. Bojongkiki-tang may bring beneficial effects to cancer-related fatigue and quality of life in cancer patients [21]. A prospective randomized controlled study indicated that, combined with chemotherapeutic agents combining iodized oil chemo-embolization, Chinese medicine comprehensive therapy could extend the pain-relieving sustained time, improve quality of life and long-term survival with less adverse reaction in primary hepatic carcinoma patients [22]. Modified Sijunzi Decoction may reduce chemotherapy elicited leucocytopenia, nausea and vomiting in colorectal cancer patients undergoing FOLFOX4 chemotherapy [23].

Chinese herbal formula, as a major application form of Chinese herb, has showed synergistic effect with conventional treatment. Yang Wei Kang Liu, a modern herbal formula, combination with chemotherapy significantly increased the survival of stage IV gastric cancer patients, and may related to activation of major pro-apoptotic pathways in gastric cancer cells [24]. Combination transcatheter arterial chemoembolization and Jiedufang significantly prolonged survival of patients from 5.87 months to 9.2 months in unresectable hepatocellular carcinoma patients [25]. For advanced breast cancer, Shengqi Fuzheng,..
a multiple-herb injection, can alleviate the bone marrow inhibition caused by chemotherapy, improve clinical symptoms and quality of life, and prolong the survival time, so as to enhance the efficacy of chemotherapy [26]. Shengqi Fuzheng is also effective in increase efficacy and reduce toxicity when combined with platinum-based chemotherapy for advanced NSCLC [27]. A retrospective analysis and comparison suggested treatment of senile advanced NSCLC with TCM alone has its apparent superiority in stabilizing tumor focus, improving clinical symptoms, elevating quality of life and prolonging the survival time [28].

In addition, Chinese herbal formula has been reported to be effective in prevent cancer metastasis. Invigorating spleen herb formula showed significantly effects to prevent metastasis in postoperative gastric cancer patient [29]. Weining granules combined with chemotherapy also inhibited recurrence and metastasis in postoperative gastric cancer [30]. Fu Zheng and Quxie herbal capsule applying in the succedent consolidating treatment for stage II and III colorectal cancer after radical operation might be favorable to reduce relapse and metastasis and improve quality of life [31]. While new drugs and approaches are being developed, combination with conventional therapies, TCM may provide new contribution to cancer treatment.

Therapeutic Mechanisms of TCM against Cancer

Same with current pharmacotherapy, Chinese herbs act on cancer cells through apoptosis, cell senescence, autophagy and other mechanisms to achieve therapeutic effects [32-33]. Apoptosis, an evolutionarily conserved cell suicide process, is a major mechanism in Chinese herb treatment. It have been reported cantharidin and Curcuma aromatica extract may induce apoptosis and G2/M cell cycle arrest in colorectal cancer cells, and related to caspase activation and cell cycle regulatory proteins [34-35]. Spatholobus suberecuss, an herb widely used in cancer treatment, inhibits cancer cell growth by inducing apoptosis and arresting cell cycle at G2/M checkpoint, and associated with DNA damage and activation of phosphor-Chk1/Chk2 [36]. Chan-Yu-Bao-Yuan-Tang, a Chinese herbal formula, induces apoptosis in lung cancer cells via a mitochondria-mediated pathway [37]. Rhein, an anthraquinone compound isolated from Rhubarb, may induce apoptosis through the endoplasmic reticulum stress, caspase- and mitochondria-dependent pathways in human tongue squamous cancer cells [38].

Cell senescence, a state of stable irreversible cell cycle arrest provoked by a variety of stimuli, also contributes to herbal therapeutic response. Ganoderiol F, a tetracyclic triterpene isolated from Ganoderma amboinense, has reported to induce cell senescence in hepatoma HepG2 cells accompanied by activation of the mitogen-activated protein kinase EKR and up-regulation of cyclin-dependent kinase inhibitor p16 [39]. Resveratrol, a polyphenol component of Polygonum cuspidatum and grapes, may induce cell senescence with attenuated mono-ubiquitination of histone H2B in glioma cells [40]. Chronic treatment with subapotoptic concentration of resveratrol may induce p53 and p21 dependent cell senescence in colorectal carcinoma cells, and related to increased level of reactive oxygen species [41]. Tenglong Buzhong Decoction, a Chinese herbal formula, is effective in induce cell senescence in colorectal carcinoma cells, which related to up-regulation of p21 and p16, and down-regulation of RB phosphorylation [42].

Autophagy, an evolutionarily conserved self-defense mechanism in which organelles and proteins are sequestered and subsequently degraded through fusion with lysosomes, has been recognized as a target for cancer treatment [43]. Licorice Glycyrrhiza glabra and its component licochalcone-A can induce autophagy in addition to apoptosis in human prostate cancer cells, accompanied by down-regulation of Bcl-2 and inhibition of the mammalian target of rapamycin (mTOR) pathway [44]. G. lucidum triterpene extract induced autophagy in colon cancer through the inhibition of p38 mitogen-activated kinase [45]. Bufalin, a major digoxin-like immunoreactive component of the Chinese medicine Chansu, could induce autophagy-mediated cell death in human colon cancer cells through reactive oxygen species generation and JNK activation [46].

In addition to directly against cancer cell, anti-angiogenesis also participate to Chinese herb elicited anti-cancer effects. Pang et al. reported that acetyl-11-keto-beta-boswellic acid, an active component of Boswellia serrata, strongly inhibits human prostate tumor growth by suppressing VEGFR-2 mediated angiogenesis [47]. Curcumin, a component of Curcuma aromatica and Curcuma longa, could inhibit angiogenesis in multiple tumor models [48-51]. Tanshinone I, a component of Salvia Miltiorrhiza, showed potent anti-angiogenesis activity in prostate cancer [52]. Decursin and decursinol angeolate, ingredients isolated from Angelica gigas, possess potential to inhibit VEGF-induced angiogenesis via suppression of the VEGF-2 signaling pathway [53].

Furthermore, Chinese herb has been reported effective in cancer prevention. Hochu-ekki-to (Bu-Zhong-Yi-Qi-Tang in Chinese), a classical Chinese herbal formula, may inhibit endometrial carcinogenesis induced by N-methyl-N-nitrosourea and 17beta-estradiol in mice [54]. Kurashige et al. reported Astrapalus extract exerts an anticarcinogenic effect in carcinogen-treated mice through activation of cytotoxic activity and the production of cytokines [55]. Adlay bran and its Ethanolic extract and residue may inhibit colonic carcinogenesis in rats [56].

Chinese Herbal Formula for Cancer Treatment

In Chinese herbalism, every herb has its own characteristics, TCM physicians believe that illness can be effectively treated by combining herbs based on their various features. Combinations of multiple herbs guided by TCM theories, called Chinese herbal formula, are the major application form of Chinese herb. Generally, Chinese herbal formula is prescribed according to patient’s body condition based on a careful differential diagnosis. But considered the special characters of cancer cells such as sustaining proliferation, immortal replication [57], TCM physicians always tend to select herbs with anti-cancer activities in Chinese herbal formula based on pharmacological studies or personal experience.

Ancient Chinese herbal formula with tumoricidal herbs can be preliminary consider as an anti-cancer formula. Such as San-Huang-Xie-Xin-Tang and Huang-lan-jiu-du-tang, which contained Rhizoma Coptis with anticancer potential could inhibit the growth of human liver cancer cells [58-59], can be used in cancer patient with corresponding syndrome. Due to the lack of appropriate ancient Chinese herbal formula for cancer, most TCM physicians extemporaneously combine multiple herbs for a formula or prescription based on TCM principles, progress in the pharmacological studies and personal experience. However, there are a certain consensuses, such as in lung cancer, Pi invigorating and phlegm removing method are the basic treatment method, and as anti-cancer herb, Smilacis Glabrae, Rhizoma Smilacis Glabreae, Herba Hedyotis Diffusae, Herba Scutellariae Barbatae were
frequently used by experts [60]. All herbs prescribed for a formula are used on the guidance of monarch, minister, assistant and guide theory. Usually, an anti-cancer herbal formula contains 3-5 herbs against cancer, and others used to enhance anti-cancer effects, ameliorate syndrome or symptoms, or reduce possible adverse reactions induced by used herbs, and totally up to 12-20 herbs for a prescription.

In addition to pharmacological synergy or antagonism between herbs or herbal components [61,62], pharmacokinetic mechanism may contribute to herb-herb interaction. In co-decoction, different combinations may influence herbal chemical components [63,64]. It has been proved intra-herb pharmacokinetics interaction between quercetin and isorhamnetin, co-transporting with each other across Caco-2 cells monolayer, the permeability ratio of isorhamnetin and quercetin increased by 4.3 and 2.2 times [65]. Both total coumarns and volatile oil, two main components of Radix Angelicae dahuricae, could improve the intestinal absorption of baicalin in vivo, and had synergistic action to enhance absorption of baicalin [66]. Although there is a concern about herb-drug interaction in chemotherapy, a literature analysis suggested most of concerns appears to be theoretical [67], and needs to be further explored. However, there is a lack of pharmacokinetic investigation about anti-cancer herbs.

Most of clinical used herbs are safety, and have been used for thousands of years. Some herbs or minerals are toxic or have predictable side effects, and have been recorded in Chinese medical literature since 100 BC, such as toad venom, croton tiglium, monkshood, realgar. TCM has developed special herb processing methods and combination rules to avoid or reduce adverse reaction. It has been reported over 90% of adverse reactions induced by herbs are owing to overdose, improper or without processing, incorrect usage of toxic drug, the confused resource or misuse of medicinal plants [68]. A few of anti-cancer herbs or Chinese Traditional Patent Medicines have certain side effects, such as pepperbox, solanum dulcamara, pleione rhizome and compound capsules cantharidin, it is important to use these herbs under the guidance of TCM theories.

There is a great need to explore the compatibility or combination rule of herbs, understand herb-herb interaction, especially anti-cancer herb-herb interaction [61]. We has purposed a syndrome differential anti-cancer and scientific anti-cancer therapeutic model, in which application of all anti-cancer herb must firstly consider its property of Chinese herb and guided by TCM theories, and in the case of herb prescription under traditional thought, herbs with anti-cancer potential can be firstly considered [69]. Base on cancer biology and pharmacology progression, the modern scientific principle also can be adapted to TCM, such as herbs with apoptosis, autophagy or senescence inducing effects can be considered for anti-cancer therapy [32,33], herbs with anokis inducing effects can be used for prevention of cancer metastasis [70].

Future Directions

TCM can be used to alleviate symptoms, improve quality of life, prevent recurrence and metastasis, and prolong survival time. Scientifically combination conventional treatment with TCM may provide new insight into future practice of cancer medicine. However, as an ancient ethnomedicine, TCM must further develop effective herbal combinations or formulas for various situations in cancer treatment, elucidate herb effect mechanisms, understand combination rule of anti-cancer herbs and herb-drug interaction, identify active herbal ingredients, and demonstrate clinical efficacy by high level randomized control trials.

Acknowledgements

This work was supported by Program from Science & Technology Commission of Shanghai Municipality (01149501300), Program for Long-Yi Scholars and Research Team in State Clinical Research Center of TCM (LYTD-04), and Key Discipline of State Administration of Traditional Chinese Medicine (Traditional Chinese Medicine in Oncology, LHZLK-1107).

References

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. World Health Organization (2008) The Global Burden of Disease: 2004 Update. World Health Organization, Geneva.
3. Anonymous (2003) The inner canon of emperor Huang [Chinese]. Chinese Medical Ancient Books Publishing House, Beijing.
4. He Y (2004) Progress in using combination of Chinese drug with chemotherapy to treat cancer. J Tradit Chin Med 24: 153-157.
5. Liu S, Hua YQ, Sun ZP, Tan S, Lu DM (2007) Breast cancer pathogenesis of stagnation of phegm, poison and blood stasis: rationale and clinical application in traditional Chinese medicine. Zhong Xi Yi Jie He Xue Bao 5: 122-125.
6. Zhou X, Tian D (2001) A review on nasopharyngeal carcinoma in ancient Chinese literature. Zhonghua Yi Shi Za Zhi 31: 115-118.
7. Wickie RW, Cheung CS (2002) Principles for applying Traditional Chinese Medicine to cases of cancer. Integr Cancer Ther 1: 175-178.
8. Du Q, Hu B, shen KP, An HM (2010) Pathogenesis and treatment law of Traditional Chinese Medicine in hepatocarcinoma. World J Integr Tradit West Med 5: 814-817.
9. Yan JG, Yao SK (2010) The study of TCM syndrome differentiation and treatment in liver cancer. J Internegr Hepatic Dis 20: 189-190.
10. Pan MQ, Tian H (1993) Employ the methods of invigorating spleen and regulating Qi to treat primary hepatic cancer. J Tradit Chinese Med 34: 239-240.
11. Li YL, Zhang SP (2000) The effects of invigorating spleen and regulating Qi in patients with primary hepatic cancer: an analysis of 127 cases. Tianjin Tradit Chinese Med 17: 12-13.
12. Yu J (2005) Doctor Shen Li uses TCM syndrome differentiation treatment in treating the side effects caused by chemo- or radiotherapies in cancer. J Zhengjiang Coll Tradit Chinese Med 29: 37-38.
13. Wand CJ, Hu Y, Fu TT, Huang XH, Dai XB, et al (2010) Syndrome distribution of primary liver cancer in Guangzhou area . Chinese Arch Tradit Chinese Med 11: 2314-2318.
14. Shi J, Lu Y, Zhang X, Wang XW, Ye M, et al (2010) Relationship between expressions of estrogen and progesterone receptors and syndrome types of gastric carcinoma. Zhong Xi Yi Jie He Xue Bao 8: 629-635.
15. Hu XM, Zhang PT, Yang ZY, Li DR, Yu MW, et al (2006) The relationship between pathological types and syndromes of TCM in non small cell lung cancer. Chinese J Inform Tradit Chinese Med 13: 19-21.
16. Sun H, Li PP (2003) The preliminary study between Syndrome Pattern of Traditional Chinese Medicine and Expression of Prognostic Factors of Breast Cancer. Chinese J Basic Med Tradit Chinese Med 9: 72-73.
17. Liu L, Xu L, Sun DZ, Wei PK (2006) Correlations of E-cadherin, matrix metalloproteinase-2 and intercellular adhesion molecule-1 expression with traditional Chinese medicine classifications of syndrome for gastric carcinoma. World Health Organization, Geneva.
18. Su W, Xu ZY, Zhao ZQ (2010) Correlation between TCM Syndrome and Genetic Polymorphism of CYP1A1 and CYP2E1 in Patients with Lung Cancer. Acta Univ Tradit Med Sine Pharmacol Shanghai 24: 29-32.
19. Mok TS, Yeo W, Johnson PJ, Hui P, Ho WM, et al. (2007) A double-
blind placebo-controlled randomized study of Chinese herbal medicine as complementary therapy for reduction of chemotherapy-induced toxicity. Ann Oncol 18: 769-774.

20. Loo WT, Lin LJ, Chow LW, Cheung MN, Wang M (2010) Rhodiola algida improves chemotherapy-induced oral mucositis in breast cancer patients. Expert Opin Investig Drugs 1: 591-100.

21. Jeong JS, Ryu BH, Kim JS, Park JW, Choi WC, et al. (2010) Bojungikki-tang for cancer-related fatigue: a pilot randomized clinical trial. Int Cancer Ther 9: 331-338.

22. Tian HQ, Li HL, Wang B, Liang GW, Huang XQ, et al. (2010) Treatment of middle-stage primary hepatic carcinoma by Chinese medicine comprehensive therapy: A prospective randomized controlled study. Chin J Integr Med 16: 102-108.

23. Xiao H, Yang J (2011) Immune enhancing effect of modified sijunzi decoction on patients with colorectal cancer undergoing chemotherapy. Zhongguo Zhong Xi Yi Jie He Za Zhi 31: 164-167.

24. Li J, Sun GZ, Lin HS, Pei YX, Qi X, et al. (2008) The herb medicine formula “Yang Wei Kang Liu” improves the survival of late stage gastric cancer patients and induces the apoptosis of human gastric cancer cell line through Fas/Fas ligand and Bax/Bcl-2 pathways. Int Immunopharmacol 8: 1196-206.

25. Yu Y, Lang Q, Chen Z, Li B, Yu C, et al. (2009) The efficacy for unresectable hepatocellular carcinoma may be improved by transcatheter arterial chemoembolization in combination with a traditional Chinese herbal medicine formula: a retrospective study. Cancer 115: 5132-5138.

26. Huang ZF, Wei JS, Li HZ, et al. (2008) Effect of Shenqi Fuzheng injection combined with chemotherapy on thirty patients with advanced breast cancer. Zhongguo Zhong Xi Yi Jie He Za Zhi 28: 152-154.

27. Dong J, Su SY, Wang MY, Zhan Z (2010) Shenqi fuzheng, an injection concocted from Chinese medicinal herbs, combined with platinum-based chemotherapy for advanced non-small cell lung cancer: a systematic review. J Exp Clin Cancer Res 29: 137.

28. Cheng JH, Liu WS, Li ZM, Wang ZG (2007) A clinical study on global TCM treatment in treating senile advanced non-small cell lung cancer. Chin J Integr Med 13: 269-274.

29. Song JJ (2004) Study of invigorating spleen prescription on postoperative metastasis of gastric cancer. Chinese J Integr Tradit West Med 13: 2956-2957.

30. Deng X, Liang J, Qing LK, Zhu CY, Li LH (2008) Weining granules combined with chemotherapy for recurrent and metastatic gastric cancer. World Chinese J Digestol 16: 175-179.

31. Luo L, Yang YF, Li PH (2006) Cohort Study on Fuzheng Capsule and Quxie Capsule in Reducing Relapse and Metastasis of Cancer in Patients with Stage II and III Colorectal Carcinoma after Operation. Zhongguo Zhong Xi Yi Jie He Za Zhi 26: 677-680.

32. Chiantore MV, Vannucchi S, Mangino G, Percario ZA, Affabris E, et al. (2009) Senescence and cell death pathways and their role in cancer therapeutic outcome. Curr Med Chem 16: 287-300.

33. Amaravadi RK, Thompson CB (2007) The roles of therapy-induced autophagy and necrosis in cancer treatment. Clin Cancer Res 13: 7271-7279.

34. Huang WW, Ko SW, Tsai HY, Chung JG, Chiang JH, et al. (2011) Cantharidin induces apoptosis in NSCLC and SCLC cell lines via a mitochondria-mediated pathway. Xenobiotica 41: 593-602.

35. Hu B, Shen KP, An HM, Wu Y, Du Q (2011) Aqueous extract of Curcuma aromatica induces apoptosis and G2/M arrest in human colon carcinoma LS-174 T cells independent of p53. Cancer Biother Radiopharm 26: 97-104.

36. Pang X, Yi Z, Zhang X, Sun B, Qu W, et al. (2009) Acetyl-11-keto-boswellic acid inhibits prostate tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis. Cancer Res 69: 5893-5900.

37. Hu B, An HM, Shen KP, Du Q (2010) Senescence-inducing effects of Chinese herbal medicine Tenglong Buzhong Decoction on human colon carcinoma LS-174 T cells and the mechanism Zhong Xi Yi Jie He Xue Bao 8: 1048-1052.

38. Lai WW, Yang JS, Lai KC, Kuo CL, Hsu CK, et al. (2009) Rhein induced apoptosis through the endoplasmic reticulum stress, caspase- and mitochondria-dependent pathways in SCC-4 human tongue squamous cancer cells. In Vivo 23: 309-316.

39. Chang UM, Li CH, Lin L, Huang CP, Kan LS, et al. (2006) Genaderol F, a ganoderma triterpene, induces senescence in hepatoma HepG2 cells. Life Sci 79: 1129-1139.

40. Gao Z, Xu MS, Barnett TL, Xu CW (2011) Resveratrol induces cellular senescence with attenuated mono-ubiquitination of histone H2B in glioma cells. Biochem Biophys Res Commun 407: 271-276.

41. Heiss EH, Schilder YD, Dirsch VM (2007) Chronic treatment with resveratrol induces redox stress- and ataxia telangiectasia-mutated (ATM)-dependent senescence in p53-positive cancer cells. J Biol Chem 282: 26759-26766.

42. Hu B, He JS, Shen KP, Du Q (2010) Senescence-inducing effects of Chinese herbal medicine Tenglong Buzhong Decoction on human colon carcinoma LS-174 T cells and the mechanism Zhong Xi Yi Jie He Xue Bao 8: 1048-1052.

43. Amaravadi RK, Lippincott-Schwartz J, Yin XM, Weiss WA, Takebe N, et al. (2011) Principles and current strategies for targeting autophagy for cancer treatment. Clin Cancer Res 17: 654-666.

44. Yo YT, Shieh GS, Hsu KF, Wu CL, Shiao AL (2009) Licorice and licochalcone-A induce autophagy in LNCaP prostate cancer cells by suppression of Bcl-2 expression and the mTOR pathway. J Agric Food Chem 57: 8266-8273.

45. Thyagarajan A, Jedinak A, Nguyen H, Terry C, Baldridge LA, et al. (2010) Triterpenes from Ganoderma Lucidum induce autophagy in colon cancer through the inhibition of p38 mitogen-activated kinase (p38 MAPK). Nutr Cancer 62: 630-640.

46. Xie CM, Chan WY, Yu S, Zhao J, Cheng CH (2011) Bufalin induces autophagy-mediated cell death in human colon cancer cells through reactive oxygen species generation and JNK activation. Free Radic Biol Med 51: 1365-1375.

47. Pang X, Yi Z, Zhang X, Sun B, Qu W, et al. (2011) Acetyl-11-keto-beta-boswellic acid inhibits prostate tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis. Cancer Res 69: 5893-5900.

48. Perry MC, Demeule M, Régina A, Mouradjian R, Béliveau R (2010) Curcumin inhibits tumor growth and angiogenesis in glioblastoma xenografts. Mol Nutr Food Res 54: 1192-1201.

49. Chakraborty G, Jain S, Kale S, Raja R, Kumar S, et al. (2008) Curcumin suppresses breast tumor angiogenesis by abrogating osteopontin-induced VEGF expression. Mol Med Report 1: 641-646.

50. Binion DG, Ottersen MF, Raflee P (2008) Curcumin inhibits VEGF-mediated angiogenesis in human intestinal microvascular endothelial cells through COX-2 and MAPK inhibition. Gut 57: 1509-1517.

51. Kunnumakkara AB, Anand P, Aggarwal BB (2008) Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through multivariate cell signaling proteins. Cancer Lett 269: 199-225.

52. Gong Y, Li Y, Lu L, Li L, Abdolmaleky H, et al. (2011) Bioactive tanoinshones in Salvia miltiorrhiza inhibit the growth of prostate cancer cells in vitro and in mice. Int J Cancer 129: 1042-1052.

53. Jung MH, Lee SH, Ahn EM, Lee YM (2009) Decursin and decursinol angelate inhibit VEGF-induced angiogenesis via suppression of the VEGFR-2-signaling pathway. Carcinogenesis 30: 655-661.

54. Onogi K, Niwa K, Tang L, Yun W, et al. (2006) Inhibitory effects of Hochu-ekki-to on endometrial carcinogenesis induced by N-methyl-N-nitrosourea and 17beta-estradiol in mice. Oncol Rep 16: 1343-1348.

55. Kurashige S, Akuzya Y, Endo F (1999) Effects of astaxanin radix extract on carcinogenesis, cytokine production, and cytotoxicity in mice treated with a carcinogen, N-butyl-N-butylnitrosourea. Cancer Invest 17: 30-35.

56. Li SC, Chen CM, Lin SH, Chiang W, Shih CK (2011) Effects of adlay bran and its ethanolic extract and residue on preeclampsia lesions of the colon in rats. J Sci Food Agric 91: 547-552.
57. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674.
58. Cheng WY, Wu SL, Hsiang CY, Li CC, Lai TY, et al. (2008) Relationship Between San-Huang-Xie-Xin-Tang and its herbal components on the gene expression profiles in HepG2 cells. Am J Chin Med 36: 763-797.
59. Hsu YL, Kuo PL, Tzeng TF, Sung SC, Yen MH, et al. (2008) Huang-lian-jie-du-tang, a traditional Chinese medicine prescription, induces cell-cycle arrest and apoptosis in human liver cancer cells in vitro and in vivo. J Gastroenterol Hepatol 23: e290–e299.
60. Wang SM, Lin LZ, Nie H (2011) Consensuses on lung cancer treatment by Chinese medicine experts from Beijing and Guangzhou and medication features in the North and South China. Zhongguo Zhong Xi Yi Jie He Za Zhi 31: 977-980.
61. Du Q, Hu B, Shen KP (2011) Compatibility of Chinese anti-cancer herb. Chinese J Exp Tradit Med Formu 16: 232-235.
62. Adams LS, Seeram NP, Hardy ML, Carpenter C, Heber D (2006) Analysis of the interactions of botanical extract combinations against the viability of prostate cancer cell lines. Evid Based Complement Alternat Med 3: 117-124.
63. Li X, Zhang Q, Wu S, Xu W, Li D (2011) Study on dynamic of chemical components of rhizoma alismatis and Evodia rutaecarpa in their compatibility [Chinese]. China J Chinese Mater Med 36: 147-149.
64. Nian QB, Liu HX, Deng SS, Ma ZJ, Huang QW (2011) Study on the changes of chemical components in compatibility of Radix Bupleuri with Radix Scutellariae. Chinese J Hosp Pharm 31: 104-107.
65. Lan K, He JL, Tian Y, Tan F, Jiang XH, et al. (2008) Intra-herb pharmacokinetics interaction between quercetin and isorhamnetin. Acta Pharmacol Sin 29: 1376-1382.
66. Liang XL, Liao ZG, Zhu JY, Zhao GW, Yang M, et al. (2012) The absorption characterization effects and mechanism of Radix Angelicae dahuricae extracts on baicalin in Radix Scutellariae using in vivo and in vitro absorption models. J Ethnopharmacol 139: 52-57.
67. Cheng CW, Fan W, Ko SG, Song L, Bian ZX (2010) Evidence-based management of herb-drug interaction in cancer chemotherapy. Explore (NY) 6: 324-329.
68. Li RR, Zhang ZJ, Wang ZJ, Wang F, Yuan ST (2011) Literature analysis on toxicity, side effect and adverse reaction of Traditional Chinese Medicine. Chinese J Exp Tradit Med Formu 16: 213-216, 221.
69. Hu B, An HM, Shen KP (2009) Syndrome differential anti-cancer and scientific anti-cancer [Chinese]. Chinese J Ethnomed and Ethnopharm 18: 33-34.
70. Simpson CD, Anyiwe K, Schimmer AD (2008) Anoikis resistance and tumor metastasis. Cancer Lett 272: 177-185.